BLOOD PLASMA MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Blood Plasma Market Size and Forecast – 2025 to 2032   

The Global Blood Plasma Market is estimated to be valued at USD 38.8 Mn in 2025 and is expected to reach USD 79.5 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 10.8% from 2025 to 2032. The market's growth is primarily driven by the increasing demand for plasma-derived products, rising prevalence of chronic diseases, and advancements in plasma collection and fractionation technologies.

Key Takeaways of the Global Blood Plasma Market:

• In 2025, immunology is expected to dominate the global blood plasma market by therapeutic indication, accounting for 23.2% of the share.
• By application, hypogammaglobulinemia is expected to hold the largest market share at 32.3% in 2025.
• In terms of product, immunoglobulins segment is expected to lead the market with a 35.6% share in 2025.
• North America is expected to lead the market with a 35.3% share in 2025 while Asia Pacific is expected to emerge as the fastest-growing region with a 30.2% share.

Market Overview:

The trend in the blood plasma industry is characterized by a growing focus on research and development activities to develop novel plasma-derived therapies, increasing collaboration between plasma collection centers and pharmaceutical companies, and the expansion of plasma collection networks worldwide. Additionally, there is a growing emphasis on improving the safety and quality of plasma-derived products through stringent regulatory guidelines and advanced testing methodologies.

Currents Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Analysis

To learn more about this report, Request sample copy

Blood Plasma Market Insights, By Product – Immunoglobulins Dominate Due to Widespread Therapeutic Applications

In terms of product, the immunoglobulins segment is expected to contribute the highest share of the market with 35.6% in 2025 owing to their widespread applications in treating various immunodeficiency disorders and autoimmune diseases. Immunoglobulins, also known as antibodies, are essential proteins produced by the immune system to neutralize pathogens and foreign substances.

The growing prevalence of primary immunodeficiency diseases (PIDs) and secondary immunodeficiency diseases (SIDs) has significantly driven the demand for immunoglobulin products. Moreover, the increasing use of immunoglobulins in the treatment of neurological disorders such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN) has further fueled the growth of this segment.

The rising geriatric population, which is more prone to immunodeficiency disorders, has also contributed to the high demand for immunoglobulins. Additionally, the development of novel immunoglobulin products with improved efficacy and safety profiles has expanded their therapeutic applications.

Blood Plasma Market Insights, By Application – Hypogammaglobulinemia Leads Due to Rising Demand for Immunoglobulin Replacement Therapy

In terms of application, the hypogammaglobulinemia segment is expected to contribute the highest share of the market with 32.3% in 2025 due to the increasing prevalence of this condition and the growing demand for effective treatments. Hypogammaglobulinemia is a disorder characterized by low levels of immunoglobulins in the blood, leading to a weakened immune system and increased susceptibility to infections. The primary treatment for hypogammaglobulinemia is immunoglobulin replacement therapy, which involves the administration of purified immunoglobulins to restore the body's ability to fight infections.

The rising incidence of primary immunodeficiency diseases, such as common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA), has significantly contributed to the growth of the hypogammaglobulinemia segment. Additionally, the increasing prevalence of secondary immunodeficiency disorders, such as those resulting from hematological malignancies, solid organ transplantation, and the use of immunosuppressive medications, has further driven the demand for immunoglobulin replacement therapy in the management of hypogammaglobulinemia.

Blood Plasma Market Insights, By Therapeutic Indication – Immunology Dominates Due to Rising Prevalence of Immune-Mediated Disorders

In terms of therapeutic indication, the immunology segment is expected to contribute the highest share of the market with 23.2% in 2025, driven by the increasing prevalence of immune-mediated disorders and the growing demand for effective immunomodulatory therapies. Immunology encompasses a wide range of conditions, including autoimmune diseases, allergies, and immunodeficiencies, which require the use of blood plasma-derived products for their management.

The rising incidence of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus (SLE), and multiple sclerosis, has significantly contributed to the growth of the immunology segment. These conditions often require the use of immunoglobulins and other plasma-derived products to modulate the immune system and control disease activity. Additionally, the increasing prevalence of allergic disorders, such as asthma and allergic rhinitis, has further driven the demand for immunomodulatory therapies derived from blood plasma.

Regional Insights

To learn more about this report, Request sample copy

North America Blood Plasma Market Analysis and Trends

North America’s dominance in the blood plasma industry can be attributed to several factors with an estimated share of 35.3% in 2025. The region boasts a well-established healthcare infrastructure, advanced research facilities, and a strong presence of key industry players. The United States, in particular, has a favorable regulatory environment and government policies that support the growth of the blood plasma market. The country's large population and high per capita healthcare expenditure also contribute to its leading position. Notable companies in the region include Grifols, S.A., CSL Limited, and Takeda Pharmaceutical Company Limited, which have made significant investments in research and development, as well as expanding their collection centers and manufacturing capabilities.

Asia Pacific Blood Plasma Market Analysis and Trends

The Asia Pacific region is expected to exhibit the fastest growth in the blood plasma industry with 30.2% in 2025. This growth can be attributed to the increasing awareness about plasma-derived therapies, rising healthcare expenditure, and improving healthcare infrastructure in the region. Countries like China and India, with their large populations and growing middle class, present significant growth opportunities. Moreover, government initiatives to promote the development of the blood plasma industry and attract foreign investments have further fueled market growth. China, in particular, has seen a surge in the number of plasma collection centers and has introduced favorable policies to support the industry. Companies such as China Biologic Products Holdings, Inc. and Shanghai RAAS Blood Products Co., Ltd. have emerged as key players in the region.

Global Blood Plasma Market Outlook for Key Countries:

U.S. Blood Plasma Market Trends

The U.S. blood plasma market remains at the forefront of the blood plasma industry, driven by its advanced healthcare system, extensive research and development activities, and the presence of major industry players. The country's large donor pool and well-established collection centers ensure a steady supply of plasma for manufacturing plasma-derived products. In October 2023, Freedom Plasma, a healthcare company, opened a new donation center in Ohio, U.S, aiming to raise awareness about the life-saving impact of plasma donation. Operated by ImmunoTek Bio Centers, the facility is expected to bring an annual economic impact of USD 5 million, creating jobs, supporting local businesses, and financially compensating donors while contributing to the global plasma supply.

Germany Blood Plasma Market Blood Plasma Market Trends

Germany's blood plasma market plays a crucial role in the Europe blood plasma market, characterized by its stringent quality standards, advanced technology adoption, and robust healthcare infrastructure. The country has a well-organized network of plasma collection centers and a strong focus on research and development. For instance, Europlasma, a Vienna-based plasma donation company and affiliate of French biopharma group LFB, inaugurated its first German donation center in Offenbach-am-Main. The launch was attended by Offenbach Mayor Sabine Groß and patient association representatives, who highlighted the critical role of plasma in producing life-saving therapies. CEO Benjamin Méry stated the center empowers local citizens to support patients with serious and rare diseases.

U.K. Blood Plasma Market Trends

The U.K. blood plasma market is experiencing significant growth, driven by increasing demand for plasma-derived therapies, advancements in fractionation technologies, and strategic initiatives aimed at enhancing domestic plasma collection and processing capabilities. For instance, in April 2023, the UK Ministry of Defence has launched the Blood Far Forward project to deliver dried blood plasma to injured soldiers within 30 minutes of injury in warzones. Unlike frozen plasma, dried plasma can be stored at room temperature and used immediately, helping to reduce deaths from major bleeding. The project is funded by the Army and developed by NHS Blood and Transplant, with future potential use in NHS Air Ambulances.

China Blood Plasma Market Trends

China blood plasma market driven by an increasing demand for plasma-derived therapies and advancements in healthcare infrastructure. Rising prevalence of chronic diseases and the aging population are significant factors propelling market expansion. Government initiatives promoting blood donation and investments in plasma collection facilities are further enhancing the availability of plasma products. As a result, China is becoming a key player in the global blood plasma market.

End User Feedback and Unmet Needs - Blood Plasma Market

End users across hospitals, diagnostic centers, and public health institutions have expressed strong appreciation for the clinical effectiveness and therapeutic reliability of plasma-derived products, particularly immunoglobulins and coagulation factors. Healthcare providers in developed markets highlight the rapid response and improved patient outcomes in cases of immunodeficiency disorders and hemophilia, citing standardized dosage formats and consistent supply as key enablers. For instance, BG Kliniken, a leading tertiary care hospital in Germany, reported a 30% reduction in emergency transfusion cases due to improved access to high-quality plasma therapies. This reinforces the market’s strength in delivering life-saving treatments, especially in high-income healthcare systems with robust procurement channels.

However, recurring challenges persist in emerging economies and rural health systems, where end-users frequently report high costs, uneven availability, and inadequate cold-chain infrastructure. A state-run hospital in Southeast Asia noted periodic shortages and unaffordable pricing, limiting consistent therapy for chronic conditions like primary immunodeficiencies. Unmet needs center on affordability, decentralized manufacturing, and scalable distribution models tailored for low-resource settings. Addressing these gaps through localized processing, AI-driven inventory forecasting, and government-subsidized programs could significantly boost adoption, enhance equity in treatment access, and catalyze long-term growth for manufacturers committed to inclusive healthcare innovation.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Request sample copy

Key Developments:

• On May 5, 2025, BIOIIFE, a subsidiary of Takeda, a leading biopharmaceutical company—began deploying the Adaptive Nomogram technology developed by Fresenius Kabi, a global healthcare company, across its plasma donation centers in the U.S. This innovation is being implemented through the Aurora Xi Plasmapheresis System and is expected to be fully operational by December 2025. The Adaptive Nomogram customizes the amount of plasma collected based on individual donor characteristics, such as weight and hematocrit levels. During USFDA-reviewed clinical trials, this technology demonstrated an approximate 11.5% increase in the average volume of plasma collected per donation.
• In July 2024, Biotest AG, a Germany-based biopharmaceutical company, laid the foundation for a comprehensive agreement with Kedrion, Italian biopharmaceutical company, for the full-scale commercialization and distribution of its immunoglobulin therapy, Yimmugo, in the U.S., following the U.S. FDA's approval of its Biologic License Application (BLA).
• In September 2024, Grifols, a global healthcare company, in partnership with Orange Business, division of the Orange Group, specializing in providing network and digital solutions has completed the first phase of a new data center and communications infrastructure in Cairo for Grifols Egypt for Plasma Derivatives (GEPD)—a joint venture with Egypt’s NSPO.
• In January 2024, Takeda Pharmaceuticals, a biopharmaceutical leader, received the U.S. FDA approval for its Immune Globulin Infusion 10% solution, an intravenous immunoglobulin treatment designed to enhance neuromuscular function and reduce impairment in adults diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP).

Top Strategies Followed by Global Blood Plasma Market Players

• Established players in the global blood plasma market are focusing on various strategies to maintain their market dominance. One of the key strategies is investing heavily in research and development (R&D) to innovate high-performance products.
  • For instance, in March 2022, the U.S. FDA has approved Rika, a new plasma collection system by Terumo Blood and Cell Technologies, which collects plasma in 35 minutes or less and includes safety features to help staff and protect donors. It will first launch at CSL Plasma centers in Denver, with more locations to follow. Rika was created to make plasma donation faster, safer, and more efficient. Terumo is expanding in the plasma industry, investing heavily in new technology.
• Mid-level players in the global blood plasma market play a crucial role by addressing the needs of price-sensitive segments without compromising on product quality. These companies strategically focus on delivering cost-effective plasma-derived therapies—such as immunoglobulins, albumin, and clotting factors—aiming to offer reliable alternatives to the high-priced products of dominant market leaders.
  • For instance, LabCorp has received the U.S. FDA approval for its UltraQual Multiplex PCR Assay, which screens donated blood plasma for HCV, HIV-1, HIV-2, and HBV in a single test. Developed by LabCorp's National Genetics Institute, the assay enhances plasma safety for biologic therapies treating immune, bleeding, and neurological disorders. Octapharma Plasma will be among the first to adopt the assay. The launch supports LabCorp’s growing focus on biologic drug development and plasma-derived medicine safety.
• Small-scale players in the market are adopting strategies such as niche specialization and technology adoption to remain competitive. These companies such as Kamada Ltd. and Biotest AG target niche markets with unique features or innovative products to differentiate themselves from larger players.

Market Report Scope

Blood Plasma Market Dynamics

To learn more about this report, Request sample copy

Blood Plasma Market Driver - Increasing demand for plasma-derived therapies

The global blood plasma industry is experiencing a significant driver in the form of increasing demand for plasma-derived therapies. As medical advancements continue to uncover the potential of plasma-based treatments, more patients are turning to these therapies for various medical conditions. Plasma-derived products, such as immunoglobulins, clotting factors, and albumin, are essential for treating a wide range of diseases, including primary immunodeficiencies, hemophilia, and chronic liver diseases. Moreover, the growing prevalence of rare diseases and the rising geriatric population worldwide are further fueling the demand for these life-saving therapies.

 Pharmaceutical companies are investing heavily in research and development to create innovative plasma-derived products, expanding treatment options for patients in need. As awareness about the efficacy of plasma-based treatments spreads among healthcare professionals and patients alike, the demand for these therapies is expected to continue its upward trajectory, driving the growth of the global blood plasma market in the coming years. For instance, Roche, a biotechnology company, announced new data from the largest global trial of its kind, showing that its Elecsys Amyloid Plasma Panel—combining pTau181 and ApoE4—can accurately rule out Alzheimer’s-related amyloid pathology using a simple blood test. Presented at the 17th CTAD congress, the findings highlight the test’s potential to reduce reliance on invasive procedures and provide early diagnostic clarity for patients with cognitive symptoms.

Blood Plasma Market Opportunity - Growing Adoption of Subcutaneous Immunoglobulin Therapy

The growing adoption of subcutaneous immunoglobulin (SCIG) therapy presents a promising opportunity for the global blood plasma market. SCIG therapy involves the administration of immunoglobulin products directly under the skin, allowing patients to self-administer the treatment at home. This route of administration offers several advantages over traditional intravenous immunoglobulin (IVIG) therapy, including improved patient convenience, reduced treatment time, and lower risk of systemic adverse reactions. The increasing preference for SCIG therapy among patients and healthcare providers is driven by its ability to enhance patient quality of life and reduce the burden on healthcare facilities.

As more patients opt for SCIG therapy, the demand for plasma-derived immunoglobulin products suitable for subcutaneous administration is expected to rise. This presents a significant growth opportunity for manufacturers in the Global Blood Plasma Market to develop and market SCIG products. Furthermore, the expanding indications for SCIG therapy, such as primary immunodeficiencies and neurological disorders, are likely to fuel the adoption of this treatment modality. To capitalize on this opportunity, market players should focus on research and development efforts to improve the formulation and delivery of SCIG products, as well as collaborate with healthcare providers to raise awareness and educate patients about the benefits of subcutaneous immunoglobulin therapy.

Analyst Opinion (Expert Opinion)

• The global blood plasma market is witnessing sustained growth driven by advancements in plasma fractionation technology, increasing prevalence of immunodeficiency and bleeding disorders, and expanding therapeutic applications across neurology, hematology, and critical care. Regulatory support, such as USFDA approvals for novel immunoglobulin therapies by Takeda and Biotest AG, along with innovations like Terumo BCT's Rika system and dried plasma initiatives by the UK Ministry of Defence, continue to improve safety, efficiency, and access. Challenges persist in terms of high production costs, ethical concerns around donor compensation, and reliance on the U.S. for the majority of global plasma collection. However, opportunities are emerging through decentralized collection models, AI-driven donor screening, and expansion into underserved markets across Asia, Africa, and the Middle East.
• Major conferences like the IPFA/PEI Plasma Product Workshops, PPTA Global Plasma Summit, and the World Plasma Congress have facilitated global dialogue on donor safety, supply chain resiliency, and self-sufficiency strategies, particularly for emerging markets. Industry-driven initiatives such as Grifols’ Egypt-based plasma infrastructure project, Freedom Plasma’s U.S. center expansion, and BioLife’s rollout of Aurora Xi with Adaptive Nomogram highlight the sector’s momentum in enhancing access, supply security, and technological modernization. These developments are expected to shape the global plasma market outlook over the next decade.

Market Segmentation

•  Product Insights (Revenue, USD Mn, 2020 - 2032)
• • Immunoglobulins
  • Albumin
  • Coagulation Factor Concentrates
    • Factor VIII
    • Factor IX
    • Von Willebrand Factor
    • Prothrombin Complex Concentrate
    • Fibrinogen Concentrates
    • Factor XIII
  • Alpha-1 Antitrypsin
  • Others
•  Application Insights (Revenue, USD Mn, 2020 - 2032)
• • Hypogammaglobulinemia
  • Immunodeficiency Diseases
  • Hemophilia
  • Von Willebrand's Disease
  • Others
•  Therapeutic Indication Insights (Revenue, USD Mn, 2020 - 2032)
• • Immunology
  • Oncology
  • Pulmonology
  • Rheumatology
  • Transplantation
  • Neurology
  • Hematology
  • Others
•  Source Insights (Revenue, USD Mn, 2020 - 2032)
• • Source Plasma
  • Recovered Plasma
•  End User Insights (Revenue, USD Mn, 2020 - 2032)
• • Hospitals & Clinics
  • Research Laboratories
  • Plasma Collection Centers
  • Academic & Research Institutes
  • Biopharmaceutical Companies
  • Others
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
• • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
• • CSL Behring
  • Grifols
  • Takeda Pharmaceutical Company Limited (formerly Shire)
  • Octapharma
  • Kedrion Biopharma
  • Bio Products Laboratory (BPL)
  • LFB Group
  • Sanquin Plasma Products
  • China Biologic Products Holdings, Inc
  • ADMA Biologics
  • GC Pharma
  • CSL Plasma
  • Emergent BioSolutions
  • Kamada
  • Centurion Pharma

Sources

Primary Research Interviews:

• Healthcare Industry Experts: Interviews with medical professionals, clinical researchers, hospital procurement managers, and transfusion medicine specialists.
• End-user Organizations: Feedback from public and private hospitals, therapeutic plasma centers, diagnostic labs, and health ministries utilizing or regulating plasma-derived therapies.

Databases:

• World Health Organization (WHO) – Global Health Observatory
• U.S. Food and Drug Administration (FDA) – Biologics and Blood Products Database
• European Medicines Agency (EMA) – Human Medicines Database
• National Institutes of Health (NIH) – ClinicalTrials.gov
• Centers for Disease Control and Prevention (CDC) – Blood Safety Surveillance Data
• UNICEF – Health and Nutrition Reports
• Global Health Data Exchange (GHDx)

Magazines:

• PharmaTimes
• BioPharm International
• Blood Journal – American Society of Hematology
• Medical Device and Diagnostics Industry (MD+DI)
• Pharma Manufacturing

Journals:

• Transfusion Medicine Reviews
• Journal of Clinical Apheresis
• Vox Sanguinis
• Journal of Thrombosis and Haemostasis
• Blood Transfusion Journal
• Journal of Immunological Methods

Newspapers:

• The New York Times – Science & Health
• Financial Times – Global Healthcare and Biotech
• The Guardian – Healthcare
• The Hindu – Science and Health
• The Economic Times – Pharma & Biotech

Associations:

• World Federation of Hemophilia (WFH)
• International Society on Thrombosis and Haemostasis (ISTH)
• International Plasma and Fractionation Association (IPFA)
• Plasma Protein Therapeutics Association (PPTA)
• American Association of Blood Banks (AABB)

Public Domain Sources:

• U.S. Department of Health and Human Services (HHS)
• U.S. Department of Commerce
• World Economic Forum (WEF)
• Indian Council of Medical Research (ICMR)
• European Commission – DG SANTE (Directorate-General for Health and Food Safety)

Proprietary Elements:

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in dark factories.
• Proprietary CMI Existing Repository of Information for Last 8 Years